296 related articles for article (PubMed ID: 28763515)
1. Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors.
Arends M; Biegstraaten M; Hughes DA; Mehta A; Elliott PM; Oder D; Watkinson OT; Vaz FM; van Kuilenburg ABP; Wanner C; Hollak CEM
PLoS One; 2017; 12(8):e0182379. PubMed ID: 28763515
[TBL] [Abstract][Full Text] [Related]
2. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
3. Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.
Lenders M; Schmitz B; Stypmann J; Duning T; Brand SM; Kurschat C; Brand E
Nephrol Dial Transplant; 2017 Dec; 32(12):2090-2097. PubMed ID: 27679524
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
5. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.
Anderson LJ; Wyatt KM; Henley W; Nikolaou V; Waldek S; Hughes DA; Pastores GM; Logan S
J Inherit Metab Dis; 2014 Nov; 37(6):969-78. PubMed ID: 24831586
[TBL] [Abstract][Full Text] [Related]
6. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.
Wanner C; Oliveira JP; Ortiz A; Mauer M; Germain DP; Linthorst GE; Serra AL; Maródi L; Mignani R; Cianciaruso B; Vujkovac B; Lemay R; Beitner-Johnson D; Waldek S; Warnock DG
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2220-8. PubMed ID: 20813854
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
Feriozzi S; Torras J; Cybulla M; Nicholls K; Sunder-Plassmann G; West M;
Clin J Am Soc Nephrol; 2012 Jan; 7(1):60-9. PubMed ID: 22246281
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
[TBL] [Abstract][Full Text] [Related]
9. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
10. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study.
Madsen CV; Granqvist H; Petersen JH; Rasmussen ÅK; Lund AM; Oturai P; Sørensen SS; Feldt-Rasmussen U
Nephrol Dial Transplant; 2019 Sep; 34(9):1525-1533. PubMed ID: 30535327
[TBL] [Abstract][Full Text] [Related]
11. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.
Warnock DG; Ortiz A; Mauer M; Linthorst GE; Oliveira JP; Serra AL; Maródi L; Mignani R; Vujkovac B; Beitner-Johnson D; Lemay R; Cole JA; Svarstad E; Waldek S; Germain DP; Wanner C;
Nephrol Dial Transplant; 2012 Mar; 27(3):1042-9. PubMed ID: 21804088
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Talbot AS; Lewis NT; Nicholls KM
Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.
Weidemann F; Niemann M; Störk S; Breunig F; Beer M; Sommer C; Herrmann S; Ertl G; Wanner C
J Intern Med; 2013 Oct; 274(4):331-41. PubMed ID: 23586858
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.
Schiffmann R; Warnock DG; Banikazemi M; Bultas J; Linthorst GE; Packman S; Sorensen SA; Wilcox WR; Desnick RJ
Nephrol Dial Transplant; 2009 Jul; 24(7):2102-11. PubMed ID: 19218538
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.
Hopkin RJ; Cabrera GH; Jefferies JL; Yang M; Ponce E; Brand E; Feldt-Rasmussen U; Germain DP; Guffon N; Jovanovic A; Kantola I; Karaa A; Martins AM; Tøndel C; Wilcox WR; Yoo HW; Burlina AP; Mauer M
Mol Genet Metab; 2023 Feb; 138(2):106967. PubMed ID: 36709533
[TBL] [Abstract][Full Text] [Related]
17. Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy.
Goicoechea M; Gomez-Preciado F; Benito S; Torras J; Torra R; Huerta A; Restrepo A; Ugalde J; Astudillo DE; Agraz I; Lopez-Mendoza M; de Arriba G; Corchete E; Quiroga B; Gutierrez MJ; Martin-Conde ML; Lopes V; Ramos C; Mendez I; Cao M; Dominguez F; Ortiz A;
Nefrologia (Engl Ed); 2021; 41(6):652-660. PubMed ID: 36165155
[TBL] [Abstract][Full Text] [Related]
18. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
[TBL] [Abstract][Full Text] [Related]
19. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
20. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
